Anti-TBC3G/ TBC1D3G/ TBC1D3C monoclonal antibody

Anti-TBC3G/ TBC1D3G/ TBC1D3C antibody for FACS & in-vivo assay

Target products collectionGo to TBC1D3G/TBC1D3G products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1784-Ab-1/ GM-Tg-hg-MP1784-Ab-2Anti-Human TBC1D3G monoclonal antibodyHuman
GM-Tg-rg-MP1784-Ab-1/ GM-Tg-rg-MP1784-Ab-2Anti-Rat TBC1D3G monoclonal antibodyRat
GM-Tg-mg-MP1784-Ab-1/ GM-Tg-mg-MP1784-Ab-2Anti-Mouse TBC1D3G monoclonal antibodyMouse
GM-Tg-cynog-MP1784-Ab-1/ GM-Tg-cynog-MP1784-Ab-2Anti-Cynomolgus/ Rhesus macaque TBC1D3G monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1784-Ab-1/ GM-Tg-felg-MP1784-Ab-2Anti-Feline TBC1D3G monoclonal antibodyFeline
GM-Tg-cang-MP1784-Ab-1/ GM-Tg-cang-MP1784-Ab-2Anti-Canine TBC1D3G monoclonal antibodyCanine
GM-Tg-bovg-MP1784-Ab-1/ GM-Tg-bovg-MP1784-Ab-2Anti-Bovine TBC1D3G monoclonal antibodyBovine
GM-Tg-equg-MP1784-Ab-1/ GM-Tg-equg-MP1784-Ab-2Anti-Equine TBC1D3G monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1784-Ab-1/ GM-Tg-hg-MP1784-Ab-2; GM-Tg-rg-MP1784-Ab-1/ GM-Tg-rg-MP1784-Ab-2;
GM-Tg-mg-MP1784-Ab-1/ GM-Tg-mg-MP1784-Ab-2; GM-Tg-cynog-MP1784-Ab-1/ GM-Tg-cynog-MP1784-Ab-2;
GM-Tg-felg-MP1784-Ab-1/ GM-Tg-felg-MP1784-Ab-2; GM-Tg-cang-MP1784-Ab-1/ GM-Tg-cang-MP1784-Ab-2;
GM-Tg-bovg-MP1784-Ab-1/ GM-Tg-bovg-MP1784-Ab-2; GM-Tg-equg-MP1784-Ab-1/ GM-Tg-equg-MP1784-Ab-2
Products NameAnti-TBC1D3G monoclonal antibody
Formatmab
Target NameTBC1D3G
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-TBC1D3G benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species TBC3G/ TBC1D3G/ TBC1D3C VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1784
    Target NameTBC1D3G
    Gene ID101060321
    Gene Symbol and SynonymsTBC1D3C,TBC1D3D,TBC1D3G
    Uniprot AccessionQ6DHY5
    Uniprot Entry NameTBC3G_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000260287
    Target ClassificationN/A

    The target: TBC1D3G, gene name: TBC1D3G, also named as TBC1D3C, TBC1D3D. Predicted to enable GTPase activator activity. Predicted to be involved in activation of GTPase activity and intracellular protein transport. Predicted to be located in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.